1. Home
  2. NRXS vs NTRB Comparison

NRXS vs NTRB Comparison

Compare NRXS & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

HOLD

Current Price

$4.44

Market Cap

76.9M

Sector

N/A

ML Signal

HOLD

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$4.96

Market Cap

72.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRXS
NTRB
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.9M
72.6M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
NRXS
NTRB
Price
$4.44
$4.96
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $11.00
N/A
AVG Volume (30 Days)
★ 146.5K
18.6K
Earning Date
11-09-2026
12-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 22.13
N/A
EPS
N/A
★ N/A
Revenue
★ $3,569,282.00
$2,036,651.00
Revenue This Year
$118.53
$4,584.65
Revenue Next Year
$101.28
$89.09
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 32.89
N/A
52 Week Low
$2.50
$2.80
52 Week High
$9.33
$9.19

Technical Indicators

Market Signals
Indicator
NRXS
NTRB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NRXS
NTRB

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Share on Social Networks: